Galapagos to Wind Down Cell Therapy Activities, Impacting 365 Employees

Dow Jones

Jan 06

By Elias Schisgall

Galapagos' board of directors agreed to wind down the Belgian pharmaceutical company's cell therapies activities in a decision that will impact roughly 365 employees globally.

The move will also lead to the closure of sites in Leiden, the Netherlands; Basel, Switzerland; and Shanghai, and as well as two U.S.-based sites in Pittsburgh and Princeton, N.J.

The company said in October that it intended to wind down cell therapy activities, but that the decision was subject to consultations with works councils in Belgium and the Netherlands. Those consultations were completed, and the board decided to move ahead with the wind-down, the company said Monday.

Galapagos Chief Executive Officer Henry Gosebruch said the company would move forward with "transformational business development" following the wind-down. The company will continue managing its non-cell therapy activities.

The company said last month it was evaluating strategic alternatives after an autoimmune disease treatment failed to meet one of its trial goals.

Galapagos American Depository Receipts rose 6.1% to $34.74 in after-hours trading.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 05, 2026 16:18 ET (21:18 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601984837"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601984837\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601984837?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 05:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601984837","market":"us","top_or_hot":-1,"title":"Galapagos to Wind Down Cell Therapy Activities, Impacting 365 Employees","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Galapagos' board of directors agreed to wind down the Belgian pharmaceutical company's cell therapies activities in a decision that will impact roughly 365 employees globally. \n</p>\n<p>\n  The move will also lead to the closure of sites in Leiden, the Netherlands; Basel, Switzerland; and Shanghai, and as well as two U.S.-based sites in Pittsburgh and Princeton, N.J. \n</p>\n<p>\n  The company said in October that it intended to wind down cell therapy activities, but that the decision was subject to consultations with works councils in Belgium and the Netherlands. Those consultations were completed, and the board decided to move ahead with the wind-down, the company said Monday. \n</p>\n<p>\n  Galapagos Chief Executive Officer Henry Gosebruch said the company would move forward with \"transformational business development\" following the wind-down. The company will continue managing its non-cell therapy activities. \n</p>\n<p>\n  The company said last month it was evaluating strategic alternatives after an autoimmune disease treatment failed to meet one of its trial goals. \n</p>\n<p>\n  Galapagos American Depository Receipts rose 6.1% to $34.74 in after-hours trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 16:18 ET (21:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galapagos to Wind Down Cell Therapy Activities, Impacting 365 Employees</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalapagos to Wind Down Cell Therapy Activities, Impacting 365 Employees\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-06 05:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Galapagos' board of directors agreed to wind down the Belgian pharmaceutical company's cell therapies activities in a decision that will impact roughly 365 employees globally. \n</p>\n<p>\n  The move will also lead to the closure of sites in Leiden, the Netherlands; Basel, Switzerland; and Shanghai, and as well as two U.S.-based sites in Pittsburgh and Princeton, N.J. \n</p>\n<p>\n  The company said in October that it intended to wind down cell therapy activities, but that the decision was subject to consultations with works councils in Belgium and the Netherlands. Those consultations were completed, and the board decided to move ahead with the wind-down, the company said Monday. \n</p>\n<p>\n  Galapagos Chief Executive Officer Henry Gosebruch said the company would move forward with \"transformational business development\" following the wind-down. The company will continue managing its non-cell therapy activities. \n</p>\n<p>\n  The company said last month it was evaluating strategic alternatives after an autoimmune disease treatment failed to meet one of its trial goals. \n</p>\n<p>\n  Galapagos American Depository Receipts rose 6.1% to $34.74 in after-hours trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 05, 2026 16:18 ET (21:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601984837","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601984837","pubTimestamp":1767647880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Galapagos' board of directors agreed to wind down the Belgian pharmaceutical company's cell therapies activities in a decision that will impact roughly 365 employees globally.The move will also lead to the closure of sites in Leiden, the Netherlands; Basel, Switzerland; and Shanghai, and as well as two U.S.-based sites in Pittsburgh and Princeton, N.J.The company said in October that it intended to wind down cell therapy activities, but that the decision was subject to consultations with works councils in Belgium and the Netherlands. Those consultations were completed, and the board decided to move ahead with the wind-down, the company said Monday.Galapagos Chief Executive Officer Henry Gosebruch said the company would move forward with \"transformational business development\" following the wind-down. The company will continue managing its non-cell therapy activities.The company said last month it was evaluating strategic alternatives after an autoimmune disease treatment failed to meet","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLPG":"Galapagos NV"},"translate_title":"加拉帕戈斯将逐步减少细胞治疗活动，影响365名员工","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLPG":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Galapagos' board of directors agreed to wind down the Belgian pharmaceutical company's cell therapies activities in a decision that will impact roughly 365 employees globally. \n\n\n  The move will also lead to the closure of sites in Leiden, the Netherlands; Basel, Switzerland; and Shanghai, and as well as two U.S.-based sites in Pittsburgh and Princeton, N.J. \n\n\n  The company said in October that it intended to wind down cell therapy activities, but that the decision was subject to consultations with works councils in Belgium and the Netherlands. Those consultations were completed, and the board decided to move ahead with the wind-down, the company said Monday. \n\n\n  Galapagos Chief Executive Officer Henry Gosebruch said the company would move forward with \"transformational business development\" following the wind-down. The company will continue managing its non-cell therapy activities. \n\n\n  The company said last month it was evaluating strategic alternatives after an autoimmune disease treatment failed to meet one of its trial goals. \n\n\n  Galapagos American Depository Receipts rose 6.1% to $34.74 in after-hours trading. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 05, 2026 16:18 ET (21:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}